<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38070892</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>09</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Cohort profile: evaluation of immune response and household transmission of SARS-CoV-2 in Costa Rica: the RESPIRA study.</ArticleTitle><Pagination><StartPage>e071284</StartPage><MedlinePgn>e071284</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e071284</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2022-071284</ELocationID><Abstract><AbstractText Label="PURPOSE">The RESPIRA cohort aims to describe the nature, magnitude, time course and efficacy of the immune response to SARS-CoV-2 infection and vaccination, population prevalence, and household transmission of COVID-19.</AbstractText><AbstractText Label="PARTICIPANTS">From November 2020, we selected age-stratified random samples of COVID-19 cases from Costa Rica confirmed by PCR. For each case, two population-based controls, matched on age, sex and census tract were recruited, supplemented with hospitalised cases and household contacts. Participants were interviewed and blood and saliva collected for antibodies and PCR tests. Participants will be followed for 2 years to assess antibody response and infection incidence.</AbstractText><AbstractText Label="FINDINGS TO DATE">Recruitment included 3860 individuals: 1150 COVID-19 cases, 1999 population controls and 719 household contacts from 304 index cases. The age and regional distribution of cases was as planned, including four age strata, 30% rural and 70% urban. The control cohort had similar sex, age and regional distribution as the cases according to the study design. Among the 1999 controls recruited, 6.8% reported at enrolment having had COVID-19 and an additional 12.5% had antibodies against SARS-CoV-2. Compliance with visits and specimens has been close to 70% during the first 18 months of follow-up. During the study, national vaccination was implemented and nearly 90% of our cohort participants were vaccinated during follow-up.</AbstractText><AbstractText Label="FUTURE PLANS">RESPIRA will enable multiple analyses, including population prevalence of infection, clinical, behavioural, immunological and genetic risk factors for SARS-CoV-2 acquisition and severity, and determinants of household transmission. We are conducting retrospective and prospective assessment of antibody levels, their determinants and their protective efficacy after infection and vaccination, the impact of long-COVID and a series of ancillary studies. Follow-up continues with bimonthly saliva collection for PCR testing and biannual blood collection for immune response analyses. Follow-up will be completed in early 2024.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">NCT04537338.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loria</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5679-7341</Identifier><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biomedicas-Fundacion Inciensa, San Jose, Costa Rica vloria@acibfunin.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aparicio</LastName><ForeName>Amada</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Caja Costarricense de Seguro Social, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildesheim</LastName><ForeName>Allan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biomedicas-Fundacion Inciensa, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cort&#xe9;s</LastName><ForeName>Bernal</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biomedicas-Fundacion Inciensa, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrientos</LastName><ForeName>Gloriana</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biomedicas-Fundacion Inciensa, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Retana</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biomedicas-Fundacion Inciensa, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Kaiyuan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of International Epidemiology and Population Studies, Fogarty International Center, NIH, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ocampo</LastName><ForeName>Rebeca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biomedicas-Fundacion Inciensa, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prevots</LastName><ForeName>D Rebecca</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Epidemiology and Population Studies Unit, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, NIAID, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Z&#xfa;&#xf1;iga</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biomedicas-Fundacion Inciensa, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waterboer</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Infections and Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong-McClure</LastName><ForeName>Roy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Caja Costarricense de Seguro Social, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morera</LastName><ForeName>Melvin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Caja Costarricense de Seguro Social, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butt</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infections and Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binder</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Virus-Associated Carcinogenesis, German Cancer Research Center, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelnour</LastName><ForeName>Arturo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital Nacional de Ni&#xf1;os, Caja Costarricense de Seguro Social, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calder&#xf3;n</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Caja Costarricense de Seguro Social, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gail</LastName><ForeName>Mitchell H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>Ruth M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sol&#xed;s</LastName><ForeName>Cristina Barboza</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Public Health Dental Department, Universidad de Costa Rica, Sabanilla de Montes de Oca, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fantin</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biomedicas-Fundacion Inciensa, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanegas</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biomedicas-Fundacion Inciensa, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercado</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;vila</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biomedicas-Fundacion Inciensa, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porras</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biomedicas-Fundacion Inciensa, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrero</LastName><ForeName>Rolando</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Agencia Costarricense de Investigaciones Biomedicas-Fundacion Inciensa, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04537338</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>HHSN261201000121C</GrantID><Acronym>CP</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>75N91020C00001</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003364" MajorTopicYN="N" Type="Geographic">Costa Rica</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">immunology</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>20</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38070892</ArticleId><ArticleId IdType="pmc">PMC10729140</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2022-071284</ArticleId><ArticleId IdType="pii">bmjopen-2022-071284</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19 related mortality, 2020-21. Lancet 2022:1513&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>Our World in Data . Costa Rica: Coronavirus pandemic country profile 2023. n.d.
Available: ourworldindata.org/coronavirus/country/costa-rica</Citation></Reference><Reference><Citation>Fantin R, Agarwala N, Aparicio A, et al. . Estimating the cumulative incidence of SARS-Cov-2 infection in Costa Rica: modeling Seroprevalence data in a population-based cohort. The Lancet Regional Health - Americas 2023;27:100616. 10.1016/j.lana.2023.100616</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2023.100616</ArticleId><ArticleId IdType="pmc">PMC10589740</ArticleId><ArticleId IdType="pubmed">37868648</ArticleId></ArticleIdList></Reference><Reference><Citation>Baj J, Karaku&#x142;a-Juchnowicz H, Teresi&#x144;ski G, et al. . COVID-19: specific and non-specific clinical manifestations and symptoms: the current state of knowledge. J Clin Med 2020;9:1753. 10.3390/jcm9061753</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9061753</ArticleId><ArticleId IdType="pmc">PMC7356953</ArticleId><ArticleId IdType="pubmed">32516940</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Xiao Z, Ye K, et al. . SARS-Cov-2: characteristics and current advances in research. Virol J 2020;17:117. 10.1186/s12985-020-01369-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-020-01369-z</ArticleId><ArticleId IdType="pmc">PMC7387805</ArticleId><ArticleId IdType="pubmed">32727485</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P, et al. . Characteristics of SARS-Cov-2 and COVID-19. Nat Rev Microbiol 2021;19:141&#x2013;54. 10.1038/s41579-020-00459-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohn MK, Hall A, Sepiashvili L, et al. . Pathophysiology of COVID-19: mechanisms underlying disease severity and progression. Physiology (Bethesda) 2020;35:288&#x2013;301. 10.1152/physiol.00019.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiol.00019.2020</ArticleId><ArticleId IdType="pmc">PMC7426542</ArticleId><ArticleId IdType="pubmed">32783610</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC . SARS-Cov-2 variant classifications and definitions 2022. 2022.</Citation></Reference><Reference><Citation>WHO . Tracking SARS-Cov-2 variants 2022. 2022.</Citation></Reference><Reference><Citation>Petrara MR, Bonfante F, Costenaro P, et al. . Asymptomatic and mild SARS-Cov-2 infections elicit lower immune activation and higher specific neutralizing antibodies in children than adults. Front Immunol 2021;12:741796. 10.3389/fimmu.2021.741796</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.741796</ArticleId><ArticleId IdType="pmc">PMC8515185</ArticleId><ArticleId IdType="pubmed">34659235</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Chiara C, Cantarutti A, Costenaro P, et al. . Long-term immune response to SARS-Cov-2 infection among children and adults after mild infection. JAMA Netw Open 2022;5:e2221616. 10.1001/jamanetworkopen.2022.21616</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.21616</ArticleId><ArticleId IdType="pmc">PMC9280400</ArticleId><ArticleId IdType="pubmed">35816313</ArticleId></ArticleIdList></Reference><Reference><Citation>Naz S, Zahoor M, Sahibzada MUK, et al. . COVID-19 and SARS-Cov-2: everything we know so far &#x2013; A comprehensive review. Open Chem 2021;19:548&#x2013;75. 10.1515/chem-2021-0049</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/chem-2021-0049</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz H, Fatima S, Mahmood H, et al. . Antibody response to SARS-Cov-2 in relation to the contributing factors in COVID-19 patients. Viral Immunol 2022;35:142&#x2013;9. 10.1089/vim.2021.0097</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2021.0097</ArticleId><ArticleId IdType="pubmed">35167759</ArticleId></ArticleIdList></Reference><Reference><Citation>Caja Costarricense del Seguro social. Memoria Institucionales 2021.</Citation></Reference><Reference><Citation>Fantin R, Herrero R, Hildesheim A, et al. . Estimating vaccine effectiveness against SARS-Cov-2 infection, hospitalization and death from Ecologic data in Costa Rica. BMC Infect Dis 2022;22. 10.1186/s12879-022-07740-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07740-5</ArticleId><ArticleId IdType="pmc">PMC9526815</ArticleId><ArticleId IdType="pubmed">36184587</ArticleId></ArticleIdList></Reference><Reference><Citation>Caja Costarricense del Seguro Social . Vacunaci&#xf3;n Contra COVID-19. 2022.</Citation></Reference><Reference><Citation>Ministerio de Salud de Costa Rica . Lineamientos Nacionales para La Vigilancia de la Enfermedad COVID-19. 2020.</Citation></Reference><Reference><Citation>Sun K, Loria V, Aparicio A, et al. . Behavioral factors and SARS-Cov-2 transmission heterogeneity within a household cohort in Costa Rica. Commun Med (Lond) 2023;3:102. 10.1038/s43856-023-00325-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-023-00325-6</ArticleId><ArticleId IdType="pmc">PMC10363136</ArticleId><ArticleId IdType="pubmed">37481623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Medical Care 1992;30:473&#x2013;83. 10.1097/00005650-199206000-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-199206000-00002</ArticleId><ArticleId IdType="pubmed">1593914</ArticleId></ArticleIdList></Reference><Reference><Citation>Langa LS, Sallent LV, D&#xed;ez SR. Interpretaci&#xf3;n de Las Pruebas Diagn&#xf3;sticas de la COVID-19. FMC - Formaci&#xf3;n M&#xe9;dica Continuada En Atenci&#xf3;n Primaria 2021;28:167&#x2013;73. 10.1016/j.fmc.2021.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fmc.2021.01.005</ArticleId><ArticleId IdType="pmc">PMC7984870</ArticleId><ArticleId IdType="pubmed">33776411</ArticleId></ArticleIdList></Reference><Reference><Citation>Uwamino Y, Nagata M, Aoki W, et al. . Accuracy and stability of saliva as a sample for reverse transcription PCR detection of SARS-Cov-2. J Clin Pathol 2021;74:67&#x2013;8. 10.1136/jclinpath-2020-206972</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jclinpath-2020-206972</ArticleId><ArticleId IdType="pubmed">32928941</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott IM, Strine MS, Watkins AE, et al. . Stability of SARS-Cov-2 RNA in Nonsupplemented saliva. Emerg Infect Dis 2021;27:1146&#x2013;50. 10.3201/eid2704.204199</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2704.204199</ArticleId><ArticleId IdType="pmc">PMC8007305</ArticleId><ArticleId IdType="pubmed">33754989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott IM, Strine MS, Watkins AE, et al. . Simply saliva: stability of SARS-Cov-2 detection negates the need for expensive collection devices. medRxiv 2020:2020.08.03.20165233. 10.1101/2020.08.03.20165233</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.08.03.20165233</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N, Roshani A, Klausner JD. Duration of COVID-19 PCR Pocitivity for Omicron vs earlier variants clinical Virology plus. Journal of Clinical Virology Plus 2022;2:100085. 10.1016/j.jcvp.2022.100085</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcvp.2022.100085</ArticleId><ArticleId IdType="pmc">PMC9123744</ArticleId><ArticleId IdType="pubmed">35615055</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt J, Murugan R, Hippchen T, et al. . From Multiplex Serology to Serolomics-A novel approach to the antibody response against the SARS-Cov-2 Proteome. Viruses 2021;13:749. 10.3390/v13050749</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050749</ArticleId><ArticleId IdType="pmc">PMC8147094</ArticleId><ArticleId IdType="pubmed">33923338</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson CP, Grayson NE, Paton RS, et al. . Detection of Neutralising antibodies to SARS-Cov-2 to determine population exposure in Scottish blood donors between March and may 2020. Euro Surveill 2020;25:2000685. 10.2807/1560-7917.ES.2020.25.42.2000685</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.42.2000685</ArticleId><ArticleId IdType="pmc">PMC7651873</ArticleId><ArticleId IdType="pubmed">33094713</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X, Wang L, Sakthivel SK, et al. . US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome Coronavirus 2. Emerg Infect Dis 2020;26:1654&#x2013;65. 10.3201/eid2608.201246</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2608.201246</ArticleId><ArticleId IdType="pmc">PMC7392423</ArticleId><ArticleId IdType="pubmed">32396505</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasudevan HN, Xu P, Servellita V, et al. . Digital Droplet PCR accurately Quantifies SARS-Cov-2 viral load from crude Lysate without nucleic acid purification. Sci Rep 2021;11:780. 10.1038/s41598-020-80715-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80715-1</ArticleId><ArticleId IdType="pmc">PMC7804156</ArticleId><ArticleId IdType="pubmed">33436939</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y, Mandel M, Bar-On YM, et al. . Protection and waning of natural and hybrid immunity to SARS-Cov-2. N Engl J Med 2022;386:2201&#x2013;12. 10.1056/NEJMoa2118946</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118946</ArticleId><ArticleId IdType="pmc">PMC9165562</ArticleId><ArticleId IdType="pubmed">35613036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>